| Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges MM Wen, NS El-Salamouni, WM El-Refaie, HA Hazzah, MM Ali, G Tosi, ... Journal of Controlled Release, 2016 | 197 | 2016 |
| Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat … AS Hanafy, RM Farid, SS ElGamal Drug development and industrial pharmacy 41 (12), 2055-2068, 2015 | 107 | 2015 |
| Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease … AS Hanafy, RM Farid, MW Helmy, SS ElGamal Drug delivery 23 (8), 3111-3122, 2016 | 97 | 2016 |
| Micro-and nanotechnology approaches to improve Parkinson's disease therapy PV Torres-Ortega, L Saludas, AS Hanafy, E Garbayo, MJ Blanco-Prieto Journal of controlled release 295, 201-213, 2019 | 74 | 2019 |
| Thermoresponsive Hyalomer intra-articular hydrogels improve monoiodoacetate-induced osteoarthritis in rats AS Hanafy, SO El-Ganainy International Journal of Pharmaceutics 573, 118859, 2020 | 44 | 2020 |
| Pulsatile core-in-cup valsartan tablet formulations: in vitro evaluation MS Sokar, AS Hanafy, AH El-Kamel, SS El-Gamal asian journal of pharmaceutical sciences 8 (4), 234-243, 2013 | 34 | 2013 |
| Blood-brain barrier models: Rationale for selection AS Hanafy, D Dietrich, G Fricker, A Lamprecht Advanced Drug Delivery Reviews 176, 113859, 2021 | 32 | 2021 |
| Novel treatment strategies for brain tumors and metastases SE El-Habashy, AM Nazief, CE Adkins, MM Wen, AH El-Kamel, ... Pharmaceutical patent analyst 3 (3), 279-296, 2014 | 31 | 2014 |
| CRISPR/Cas9 delivery potentials in Alzheimer’s disease management: a mini review AS Hanafy, S Schoch, A Lamprecht Pharmaceutics 12 (9), 801, 2020 | 22 | 2020 |
| Intranasal galantamine/chitosan complex nanoparticles elicit neuroprotection potentials in rat brains via antioxidant effect LS Kandil, RM Farid, SS ElGamal, AS Hanafy Drug Development and Industrial Pharmacy 47 (5), 735-740, 2021 | 14 | 2021 |
| Galantamine nanoparticles outperform oral galantamine in an Alzheimer’s rat model: pharmacokinetics and pharmacodynamics SO El-Ganainy, MA Gowayed, M Agami, P Mohamed, M Belal, RM Farid, ... Nanomedicine 16 (15), 1281-1296, 2021 | 13 | 2021 |
| Design of chronomodulated drug delivery system of valsartan: in vitro characterization M Sokar, A Hanafy, A Elkamel, S El-Gamal Indian Journal of Pharmaceutical Sciences 77 (4), 470, 2015 | 11 | 2015 |
| Galantamine transdermal patch shows higher tolerability over oral galantamine in rheumatoid arthritis rat model LS Kandil, AS Hanafy, SA Abdelhady Drug Development and Industrial Pharmacy 46 (6), 996-1004, 2020 | 10 | 2020 |
| Subcellular analysis of blood-brain barrier function by micro-impalement of vessels in acute brain slices AS Hanafy, P Steinlein, J Pitsch, MH Silva, N Vana, AJ Becker, ... Nature Communications 14 (1), 481, 2023 | 6 | 2023 |
| Hyaluronic-benzydamine oromucosal films outperform conventional mouth rinse in ulcer healing NS El-Salamouni, AS Hanafy Journal of Drug Delivery Science and Technology 65, 102690, 2021 | 6 | 2021 |
| Stereotaxic-assisted gene therapy in Alzheimer’s and Parkinson’s diseases: therapeutic potentials and clinical frontiers SO El Ganainy, T Cijsouw, MA Ali, S Schoch, AS Hanafy Expert Review of Neurotherapeutics 22 (4), 319-335, 2022 | 5 | 2022 |
| Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer’s model AS Hanafy, A Lamprecht, D Dietrich Fluids and Barriers of the CNS 20 (1), 85, 2023 | | 2023 |
| Nanobiotechnology in Parkinson’s Disease PV Torres-Ortega, I Martínez-Valbuena, G Martí-Andrés, AS Hanafy, ... Nanobiotechnology in Neurodegenerative Diseases, 177-208, 2019 | | 2019 |
Ragwa M. FaridProfessor of Pharmaceutics, Department of Pharmaceutics, Pharos UniversityVerified email at pua.edu.eg
